Gastric Hypersecretory Conditions

• FDA approval · 2022-03-04
  FDA Approved: OMEPRAZOLE — Supplemental Application (Camber Pharmaceuticals, Inc.)

  FDA approved a supplemental application for Camber Pharmaceuticals' Omeprazole, a generic proton pump inhibitor, under the ANDA process.

• FDA label_change · 2020-01-07
  FDA Approved: FAMOTIDINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)

  FDA notes a supplemental application for famotidine by Lupin Pharmaceuticals, likely involving labeling changes for the drug.